Taro Pharmaceutical Industries Ltd. (TARO): Price and Financial Metrics


Taro Pharmaceutical Industries Ltd. (TARO): $27.88

-1.51 (-5.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TARO POWR Grades

  • Sentiment is the dimension where TARO ranks best; there it ranks ahead of 90.75% of US stocks.
  • TARO's strongest trending metric is Momentum; it's been moving up over the last 178 days.
  • TARO's current lowest rank is in the Momentum metric (where it is better than 24.4% of US stocks).

TARO Stock Summary

  • The ratio of debt to operating expenses for TARO PHARMACEUTICAL INDUSTRIES LTD is higher than it is for about only 0.52% of US stocks.
  • TARO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 15.59% of US stocks.
  • Over the past twelve months, TARO has reported earnings growth of -1,171.59%, putting it ahead of only 1.31% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to TARO PHARMACEUTICAL INDUSTRIES LTD, a group of peers worth examining would be UPC, WAVE, CNEY, RLX, and FALC.
  • TARO's SEC filings can be seen here. And to visit TARO PHARMACEUTICAL INDUSTRIES LTD's official web site, go to www.taro.com.

TARO Valuation Summary

  • TARO's price/earnings ratio is 17; this is 26.72% lower than that of the median Healthcare stock.
  • TARO's price/sales ratio has moved down 0.3 over the prior 243 months.

Below are key valuation metrics over time for TARO.

Stock Date P/S P/B P/E EV/EBIT
TARO 2022-11-25 1.9 0.6 17.0 14.2
TARO 2022-11-23 1.9 0.6 16.7 13.9
TARO 2022-11-22 1.9 0.6 16.9 14.1
TARO 2022-11-21 1.9 0.6 16.3 13.5
TARO 2022-11-18 1.8 0.6 16.0 13.2
TARO 2022-11-17 1.8 0.6 16.2 13.4

TARO Growth Metrics

    Its 5 year revenue growth rate is now at -32.18%.
  • The 5 year net income to common stockholders growth rate now stands at -54.85%.
  • Its year over year net income to common stockholders growth rate is now at -258.31%.
TARO's revenue has moved down $384,320,000 over the prior 70 months.

The table below shows TARO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 566.431 -148.901 1.077
2021-09-30 567.592 85.894 7.683
2021-06-30 578.449 25.653 29.498
2021-03-31 548.97 45.77 -386.653
2021-03-31 548.97 45.77 -386.653
2020-12-31 575.562 NA -302.671

TARO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TARO has a Quality Grade of B, ranking ahead of 81% of graded US stocks.
  • TARO's asset turnover comes in at 0.239 -- ranking 182nd of 682 Pharmaceutical Products stocks.
  • ELTP, ADMP, and ENTA are the stocks whose asset turnover ratios are most correlated with TARO.

The table below shows TARO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.239 0.511 -0.005
2021-06-30 0.243 0.535 0.011
2021-03-31 0.231 0.540 -0.326
2021-03-31 0.231 0.540 -0.310
2020-12-31 0.244 0.559 -0.238
2020-09-30 0.249 0.588 -0.202

TARO Stock Price Chart Interactive Chart >

Price chart for TARO

TARO Price/Volume Stats

Current price $27.88 52-week high $54.57
Prev. close $29.39 52-week low $27.50
Day low $27.80 Volume 14,000
Day high $29.07 Avg. volume 22,721
50-day MA $29.93 Dividend yield N/A
200-day MA $36.69 Market Cap 1.05B

Taro Pharmaceutical Industries Ltd. (TARO) Company Bio


Taro Pharmaceutical Industries offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1959 and is based in Haifa Bay, Israel.


TARO Latest News Stream


Event/Time News Detail
Loading, please wait...

TARO Latest Social Stream


Loading social stream, please wait...

View Full TARO Social Stream

Latest TARO News From Around the Web

Below are the latest news stories about TARO PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TARO as an investment opportunity.

Taro Pharmaceutical (TARO) Reports Q2 Loss, Misses Revenue Estimates

Taro (TARO) delivered earnings and revenue surprises of -108.33% and 18.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | October 27, 2022

Taro Provides Results for September 30, 2022

HAWTHORNE, N.Y., October 27, 2022--TARO PROVIDES RESULTS FOR SEPTEMBER 30, 2022

Yahoo | October 27, 2022

Taro to Release Second Quarter Results on October 27, 2022

HAWTHORNE, N.Y., October 24, 2022--Taro to Release Second Quarter results on October 27, 2022

Yahoo | October 24, 2022

The five-year shareholder returns and company earnings persist lower as Taro Pharmaceutical Industries (NYSE:TARO) stock falls a further 8.9% in past week

We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly...

Yahoo | October 12, 2022

H.C. Wainwright Keeps Their Buy Rating on Taro Pharmaceutical (TARO)

E ratio of 14.12.

Catie Powers on TipRanks | August 15, 2022

Read More 'TARO' Stories Here

TARO Price Returns

1-mo -13.68%
3-mo -17.17%
6-mo -23.20%
1-year -47.70%
3-year -71.18%
5-year -74.02%
YTD -44.36%
2021 -31.75%
2020 -16.50%
2019 3.89%
2018 -19.17%
2017 -0.53%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7313 seconds.